At the start of this past winter, things were a little dicey. because we were nervous about the trifecta.
That's the flu, RSV and SARSCoV-two, the virus that causes COVID. We heard about kids filling up hospitals with two or all three of these respiratory infections.
Fortunately, it turned out to be a mild flu season. But, Dave, what we didn't anticipate was how much the avian flu would decimate chicken populations.
Yeah, there are still fears about that virus, the H5-N1 could end up circulating among humans and cause the next pandemic. As for COVID, even though it wasn't worse this winter, it was still killing between four to five hundred people a day in the US.
At the start of this year, it's killed one point two million Americans. The plan now is to offer annual COVID vaccines.
Finally, RSV - it's a cold weather virus that normally hits young children but can threaten older adults as well. In fact, over one hundred thousand seniors are hospitalized every year for it.
Until recently, there were no RSV vaccines but there are several in the works. One approach is to attack the virus before the respiratory cells become infected.
The FDA has approved two for older adults and is continuing to review several others. They're up to 85% effective in preventing severe disease and hospitalization.
Here is a really cool part. When pregnant mothers were vaccinated, immunity was transferred to the fetus which would protect the baby in their vulnerable first year of life.
You can now hear additional episodes on many of your favorite podcast providers - visit Buzzsprout to subscribe.
More Information
New RSV vaccines are coming. This is very, very good news
The vaccines, along with other preventative treatments, could change cold season as we know it...
RSV vaccines for babies and adults are on the way. Here's what the CDC is saying about them
A federal advisory committee earlier this year discussed promising results of new vaccines and treatments for RSV while raising some concerns about the products that are currently under Food and Drug Administration review...
The first ever vaccine against RSV could be approved in 2023
Although usually mild, the respiratory syncytial virus can be fatal among babies and older people. Promising results from trials during pregnancy and in those aged 60 or over suggest that a vaccine may soon be approved...